The Treaty is still subject to change but its terms would currently result in the effects discussed below for EU trade marks and designs in the UK after Brexit.

The referral has been assigned the case no. C- 471/14 (Seattle Genetics), and has implications for both pending SPC applications and granted SPCs.

The draft Treaty (found here) is very wide-ranging but includes a specific section relating to its proposals for the treatment of certain types of Intellectual ...

A SPC is a unique intellectual property right that can give up to 5 years additional protection for a medicinal or veterinary product or a plant protection product covered by a patent after the patent term has expired.

The UK has now given formal notice to the EU under Art 50 of the Treaty of Lisbon of its intention to leave the EU.

A recent EPO Board of Appeal decision has highlighted a difference between the scope of protection provided by different types of second medical use claims.

At the moment, no-one can be certain about the effect of Brexit on trade marks or the transitional arrangements that will be put in place.

After much hype and almost equal amounts of disillusionment, AM (additive manufacturing) is now finding real-world commercial scale application in an increasing range of industries.

The European Patent Office (EPO) is making significant inroads into its notorious patent examination and opposition backlogs.

In March 2016 we reported on the various changes to the European Union Trade Mark Regulation, many of which came into force on 23 March 2016.

Last week the Court of Appeal issued its decision in the long running dispute between Société des Produits Nestlé S.A. and Cadbury UK Ltd...

Brand protection is essential, particularly in the highly competitive, fast-paced Food and Drink (F&D) industry.

In March 2016 and October 2017, we reported on the various changes to the European Union Trade Mark Regulation. Corresponding changes were made to the revised EU Trade Mark Directive ...

On 1 February 2017 the Board of Appeal of the EPO upheld the revocation of Bristol-Myers Squibb's (BMS) patent for anti-cancer drug dasatinib due to a lack of inventive step.

Since October 2014 the scope of the UK IPO's Opinion Service has been expanded to give it more "teeth".

On 1 February 2017 the Board of Appeal of the EPO upheld the revocation of Bristol-Myers Squibb's (BMS) patent for anti-cancer drug dasatinib due to a lack of inventive step.

The UK's highest court has held that patents directed towards new medical uses for known products must disclose some sound scientific reasoning or directly relevant experimental evidence in suppor

Last week I had the honor of speaking at the 27th Annual Pharmaceutical/Chemical Patent Practice Update put on by the New Jersey Intellectual Property Law Association’s Chemical Practice Committee.

A final stage in the successful prosecution of European patent applications is the issuance by the European Patent Office (EPO) of a Notice of Allowance Communication under Rule 71(3) EPC.

What you need to know and do starting from now.